Boston Scientific To Acquire Axonics For About $3.7 Billion
By Ben Glickman
Boston Scientific will acquire Axonics for about $3.7 billion in cash.
The companies said on Monday that Axonics had agreed to be bought for $71 a share. Boston Scientific said the deal gave Axonics an equity value of $3.7 billion and an enterprise value of $3.4 billion.
Axonics is developing medical technology focused on treating urinary and bowel issues.
Boston Scientific said the deal would add technologies to its portfolio to further serve urologists.
The deal is expected to close in the first half of 2024, subject to the approval of Axonics stockholders and the receipt of regulatory approvals.
Axonics will become a wholly-owned subsidiary of Boston Scientific.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 08, 2024 07:26 ET (12:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst